Navigation Links
BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
Date:3/30/2009

Phase 1 clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: expected action by the United States Patent and Trademark Office, the continued development and commercialization of Kuvan and BioMarin's other products and product candidates and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: actions by the United States Patent and Trademark Office, our success in the continued commercialization of Kuvan; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 10-Q and Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R)
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin to Present at the 4th Annual Citi Biotech Day
2. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
3. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
4. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
5. BioMarin to Present at the Piper Jaffray Healthcare Conference
6. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
7. BioMarin to Present at the Credit Suisse Healthcare Conference
8. BioMarin Announces Third Quarter 2008 Financial Results
9. BioMarin Corrects Information Included in Bloomberg Article
10. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
11. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, today announced financial results for the period ... Financial Summary: , Reported cash and cash equivalents ... $137,000 at December 31, 2013.  , Reported a ...
(Date:7/25/2014)... July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... June 30, 2014, after market close on Thursday, August 14, ... to the market opening on Friday, August 15, 2014, at ... China Standard Time) to review the Company,s financial results and ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
(Date:7/24/2014)... 2014  ECC West Africa, LLC (ECC) signed a ... University College Hospital (UCH) Ibadan Board of Management for ... design, construct, and operate and maintain a new, state-of-the-art ... Under the first of the 4-phase project, ECC will ... applications. UCH Ibadan intends to finance and develop the ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... July 27, 2011 /PRNewswire/ -- bioTheranostics, a ... support targeted disease management, announced today study results published ... Molecular Diagnostics related to the clinical validity and ... classification test to aid in the determination of the ...
... Midwest health care startups reported $315 million in total ... 2011, according to the BioEnterprise Midwest ... ) "While the number of companies funded ... dollars invested is down compared to recent years," said ...
... CHICAGO, July 26, 2011 Linden LLC, a ... it has made an investment in Strata Pathology ... in New England. Headquartered in Lexington, ... dermatology, urology, podiatry, oral pathology, gastroenterology and gynecology ...
Cached Biology Technology:New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility 2New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility 3Midwest Health Care Startups Raise $315 Million in First Half of 2011 2Midwest Health Care Startups Raise $315 Million in First Half of 2011 3Midwest Health Care Startups Raise $315 Million in First Half of 2011 4Linden Enters Anatomic Pathology Sector Through Investment in Strata Pathology Services, Inc. 2
(Date:7/25/2014)... of diffusion tensor tractography (DTT), which is derived ... estimation for three motor tracts, such as the ... pathway became possible. The corticospinal tract is known ... function in the human brain. Several studies have ... transtentorial herniation. In addition, some studies have demonstrated ...
(Date:7/25/2014)... 2014 Biometrics industry expands and ... digital technology for online & commerce payments while seeking ... GOOG ), LifeLock Inc. (NYSE: ... Apple Inc. (NASDAQ: AAPL ) and Fortinet ... a biometric authentication company focused on the growing m-commerce ...
(Date:7/24/2014)... NY (July 24, 2014) Scientists at The ... are one step closer to creating a viable ... patient,s own cells. , For the first ... cells lines from skin samples of patients with ... an accelerated protocol to induce these stem cells ...
Breaking Biology News(10 mins):Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... Bethesda, MD (July 29, 2010): Today, the Association for Molecular ... for Information made by the National Institutes of Health (NIH) ... survey of its membership to formulate a comprehensive response to ... in a clinical laboratory setting, AMP is able to inform ...
... call "white graphene" may be the perfect sidekick for ... nanoscale electronics. But single-atom-thick layers of hexagonal boron ... University,s world-class Department of Mechanical Engineering and Materials Science, ... Researchers in the lab of Pulickel Ajayan, Rice,s ...
... CA July 28, 2010 For Immediate Release ... normally produced in the brain may provide the starting point ... epileptic seizures, according to a new study by scientists at ... a new angle for developing drugs to treat seizures," says ...
Cached Biology News:AMP responds to Genetic Test Registry request for information 2'White graphene' to the rescue 2Scripps research study opens the door to new class of drugs for epileptic seizures 2Scripps research study opens the door to new class of drugs for epileptic seizures 3
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Gentamicin sulfate, 5g...
Biology Products: